Overview of Biologically Active Nucleoside Phosphonates

Overview

Journal Front Chem

Specialty Chemistry

Date 2021 Jan 25

PMID 33490040

Citations 13

Authors

Elisabetta Groaz

Steven De Jonghe

Affiliations

Soon will be listed here.

Abstract

The use of the phosphonate motif featuring a carbon-phosphorous bond as bioisosteric replacement of the labile P-O bond is widely recognized as an attractive structural concept in different areas of medicinal chemistry, since it addresses the very fundamental principles of enzymatic stability and minimized metabolic activation. This review discusses the most influential successes in drug design with special emphasis on nucleoside phosphonates and their prodrugs as antiviral and cancer treatment agents. A description of structurally related analogs able to interfere with the transmission of other infectious diseases caused by pathogens like bacteria and parasites will then follow. Finally, molecules acting as agonists/antagonists of P2X and P2Y receptors along with nucleotidase inhibitors will also be covered. This review aims to guide readers through the fundamentals of nucleoside phosphonate therapeutics in order to inspire the future design of molecules to target infections that are refractory to currently available therapeutic options.

Citing Articles

Mpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development.

Eslamkhah S, Aslan E, Yavas C, Akcali N, Batur L, Abuaisha A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39777535 DOI: 10.1007/s00210-024-03649-9.

Building Metabolically Stable and Potent Anti-HIV Thioether-Lipid Analogues of Tenofovir Exalidex: A thorough Pharmacological Analysis.

DErasmo M, Sharma S, Pribut N, Basson A, Dasari M, Bartsch P J Med Chem. 2024; 67(20):18204-18220.

PMID: 39411803 PMC: 11513920. DOI: 10.1021/acs.jmedchem.4c01510.

Small Molecule Drugs Targeting Viral Polymerases.

Palazzotti D, Sguilla M, Manfroni G, Cecchetti V, Astolfi A, Letizia Barreca M Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794231 PMC: 11124969. DOI: 10.3390/ph17050661.

CNS Viral Infections-What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches.

Sun M, Manson M, Guo T, de Lange E CNS Drugs. 2024; 38(5):349-373.

PMID: 38580795 PMC: 11026214. DOI: 10.1007/s40263-024-01082-3.

Design of Cell-Permeable Inhibitors of Eukaryotic Translation Initiation Factor 4E (eIF4E) for Inhibiting Aberrant Cap-Dependent Translation in Cancer.

Cardenas E, ORourke R, Menon A, Meagher J, Stuckey J, Garner A J Med Chem. 2023; 66(15):10734-10745.

PMID: 37471629 PMC: 11469893. DOI: 10.1021/acs.jmedchem.3c00917.

References

Giesler K, Liotta D . Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release. J Med Chem. 2016; 59(22):10244-10252. PMC: 5776677. DOI: 10.1021/acs.jmedchem.6b01292. View

Williams-Aziz S, Hartline C, Harden E, Daily S, Prichard M, Kushner N . Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother. 2005; 49(9):3724-33. PMC: 1195409. DOI: 10.1128/AAC.49.9.3724-3733.2005. View

Giesler K, Marengo J, Liotta D . Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity. J Med Chem. 2016; 59(15):7097-110. PMC: 5776679. DOI: 10.1021/acs.jmedchem.6b00428. View

Lee W, He G, Eisenberg E, Cihlar T, Swaminathan S, Mulato A . Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005; 49(5):1898-906. PMC: 1087627. DOI: 10.1128/AAC.49.5.1898-1906.2005. View

Painter G, Almond M, Trost L, Lampert B, Neyts J, De Clercq E . Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother. 2007; 51(10):3505-9. PMC: 2043283. DOI: 10.1128/AAC.00460-07. View

Liekens S, Andrei G, Vandeputte M, De Clercq E, Neyts J . Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res. 1998; 58(12):2562-7. View

Kern E, Hartline C, Harden E, Keith K, Rodriguez N, Beadle J . Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother. 2002; 46(4):991-5. PMC: 127114. DOI: 10.1128/AAC.46.4.991-995.2002. View

Painter W, Robertson A, Trost L, Godkin S, Lampert B, Painter G . First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 2012; 56(5):2726-34. PMC: 3346600. DOI: 10.1128/AAC.05983-11. View

Peters M, Hann Hw H, Martin P, Heathcote E, Buggisch P, Rubin R . Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2003; 126(1):91-101. DOI: 10.1053/j.gastro.2003.10.051. View

10.

Luo M, Groaz E, De Jonghe S, Snoeck R, Andrei G, Herdewijn P . Amidate Prodrugs of Cyclic 9-()-[3-Hydroxy-2-(phosphonomethoxy)propyl]adenine with Potent Anti-Herpesvirus Activity. ACS Med Chem Lett. 2018; 9(4):381-385. PMC: 5900341. DOI: 10.1021/acsmedchemlett.8b00079. View

11.

Beadle J, Hartline C, Aldern K, Rodriguez N, Harden E, Kern E . Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother. 2002; 46(8):2381-6. PMC: 127379. DOI: 10.1128/AAC.46.8.2381-2386.2002. View

12.

Peterson L, Kim J, Kijek P, Mitchell S, Hilfinger J, Breitenbach J . Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir. Bioorg Med Chem Lett. 2011; 21(13):4045-9. PMC: 3115518. DOI: 10.1016/j.bmcl.2011.04.126. View

13.

Kearney B, Flaherty J, Shah J . Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004; 43(9):595-612. DOI: 10.2165/00003088-200443090-00003. View

14.

Levesque S, Lavoie E, Lecka J, Bigonnesse F, Sevigny J . Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases. Br J Pharmacol. 2007; 152(1):141-50. PMC: 1978278. DOI: 10.1038/sj.bjp.0707361. View

15.

Fung J, Lai C, Yuen M . LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2008; 17(10):1581-8. DOI: 10.1517/13543784.17.10.1581. View

16.

Eliahu S, Camden J, Lecka J, Weisman G, Sevigny J, Gelinas S . Identification of hydrolytically stable and selective P2Y(1) receptor agonists. Eur J Med Chem. 2008; 44(4):1525-36. PMC: 4354951. DOI: 10.1016/j.ejmech.2008.07.015. View

17.

Baszczynski O, Janeba Z . Medicinal chemistry of fluorinated cyclic and acyclic nucleoside phosphonates. Med Res Rev. 2013; 33(6):1304-44. DOI: 10.1002/med.21296. View

18.

Ono-Nita S, Kato N, Shiratori Y, Carrilho F, Omata M . Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother. 2002; 46(8):2602-5. PMC: 127322. DOI: 10.1128/AAC.46.8.2602-2605.2002. View

19.

Ho E, Lin D, Mendel D, Cihlar T . Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000; 11(3):383-393. DOI: 10.1681/ASN.V113383. View

20.

Heathcote E, Marcellin P, Buti M, Gane E, de Man R, Krastev Z . Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2010; 140(1):132-43. DOI: 10.1053/j.gastro.2010.10.011. View